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Abstract
Background: Breast cancer is one of the most prevalent forms of cancer in women. Breast-speciﬁc gamma imaging
(BSGI) is a diagnostic imaging method that uses sestamibi-labelled 99Tc and a dedicated gamma camera to localize
malignant lesions in breast tissue. The aim of this study is to investigate if the current acquisition protocol for BSGI at
our hospital is optimized for the detection of lesions in our patients.
Methods: We analyzed patient data and performed a phantom study with a Dilon 6800 gamma camera. The patient
data were collected from a group of 13 patients (740 MBq 99mTc-sestamibi , four views per patient were dynamically
acquired with a frame duration of 30 s per frame and a total acquisition time of 8 min per view). Reduced-time static
images were created, and contrast-to-noise ratios of identiﬁed hotspots were determined for diﬀerent acquisition
times. For the phantom study, we used a contrast detail phantom to investigate the contrast and resolution
properties, within the range of relevant clinical acquisition parameters. The phantom was ﬁlled with a concentration
of 80 MBq in 500 ml of water, and we dynamically acquired frames for a total acquisition time of 60 min using a
general purpose (GP) collimator. To compare the GP collimator with the high-resolution collimator, a second
acquisition was made for both collimators with a total acquisition time of 16 min.
Results: The initial analysis of BSGI scans of the 13 patients showed that a dose reduction by a factor of 3 would not
have reduced the number of observable hotspots in each of the acquired views. However, a subsequent systematic
analysis of our protocol with a contrast-detail phantom showed that dose reduction results in a lower observability of
hotspots, whereas increased doses resulted in a higher observability.
Conclusion: We believe that the results of our phantom study are relevant for clinical practice and that further dose
reduction cannot be recommended for the BSGI exams at our hospital and that an increase of the administered
activity should be considered.
Keywords: Breast cancer, Scintimammography, 99mTc-sestamibi, Breast-speciﬁc gamma imaging,
Contrast-detail phantom, CNR analysis
Background
Breast cancer is one of the most prevalent forms of can-
cer in women. In the Netherlands, every year 13,000
new cases are reported, and it is a condition that aﬀects
one in every nine women. Patients with breast cancer
have a good prognosis if the disease is detected early.
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Mammography is the standard modality of choice for
screening and diagnosing breast cancer. Unfortunately,
the mammogram is not conclusive in all cases, especially
in women with dense breast tissue; mammograms can be
diﬃcult to interpret and can lead to ambiguous ﬁndings.
As a result, these patients are referred for a magnetic reso-
nance imaging (MRI) scan. BreastMRI has a high sensitiv-
ity for detecting malignancy in the breast, but speciﬁcity
is sub-optimal, potentially leading to unnecessary invasive
procedures [1]. Breast-speciﬁc gamma imaging (BSGI) is
an improved breast scintigraphy technique that uses a
© 2013 Dickerscheid et al.; licensee Springer. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
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sensitive single-head small-ﬁeld-of-view gamma camera
[2-4]. Patient dose minimisation is an important aspect of
the optimisation of any nuclear medicine protocol. The
importance of dose optimisation depends, among oth-
ers, on the patient population. For population screening,
a much lower patient dose is acceptable than that for a
patient group with a high risk of malignancy because in
the screening setting, the number of subjects is higher
and the chance of an individual positive ﬁnding is much
lower. The average mean glandular radiation dose for a
two-view digital mammography is 3.7 mGy [5] , from
which we estimate the patient dose (using ICRP 103 using
a weighting factor of 0.12) for a four-view mamography
exam to be 0.88 mSv. For a typical BSGI examination, the
patient dose varies between 5.9 and 9.4 mSv for an admin-
istered activity of 740 to 1, 184 MBq of 99mTc-sestamibi.
Recent work by Hruska et al. showed that signiﬁcant dose
reductions could be achieved when a dual-head breast-
speciﬁc gamma camera is used [6,7]. At our hospital, we
have a single-head breast-speciﬁc gamma camera (Dilon
6800, Dilon Technologies Inc., Newport News, VA, USA)
for which we want to explore the possibilities of reduc-
ing acquisition times or, equivalently, further reducing
patient dose. Speciﬁcally, this study concentrates on dose
optimisation of the BSGI protocol at our hospital, and
we introduce a contrast-to-noise ratio (CNR) analysis
methodology and a phantom-based approach to deter-
mine if imaging longer (or equivalently giving a higher
dose) could lead to the observation of more hotspots. We




The acquisition protocol at our hospital consists of a sin-
gle dose of 740 MBq of 99mTc-sestamibi (5.9 mSv) that
is administered intravenously to the patient. On average,
the acquisition of images started 22 min p.i. Subsequently,
craniocaudal (CC) and mediolateral oblique (MLO) views
are acquired for each breast. The four views (RCC, RMLO,
LCC, LMLO) are acquired with a general-purpose col-
limator for 8 min per view using a matrix size of 80 ×
80 pixels and a pixel size of 3.2 mm × 3.2 mm. Our
acquisition protocol has been adapted from the scinti-
mammography protocol of the Dutch Society of Nuclear
Medicine (NVNG) and is in line with the guidelines of the
SNM [8] and the EANM [9]. For this study, we analyzed
data from 13 patients (all patients were female, age range
43 to 66 years; mean 50.9 years) who were all referred
to our department because of known or suspected malig-
nant disease. The patient exams were performed using a
dynamic acquisition mode, with a frame duration of 30 s
per frame and a total acquisition time of 8 min. From the
acquired data, we determined the background count rates,
hotspot contrasts and hotspot sizes for diﬀerent acquisi-
tion times. From the acquired views, a total of 49 views
were included in the study (one patient had previously
undergone a breast resection, and for another patient, the
acquisition time from one of the views was reduced to 5
min due to patient discomfort). We derived time-reduced
static images, from the dynamic data, for acquisition times
of 2, 2.67, 4 and 8 min. The 8-min static views were used
for routine diagnostic purposes.We used the reports from
the nuclear medicine physicians as the reference from
which we identiﬁed all the clinically relevant hotspots for
which we determined the CNR.
Based on the retrospective nature of this study, IRB was
waived by the Medical Ethics Review Committee of St.
Antonius Hospital.
Contrast-detail phantom and acquisition
To simulate the hotspots that we see on the scinti-
mammography images in clinical practice, we used a
contrast-detail (CD) phantom which shows ‘hot’ areas or
lesions of varying sizes and contrasts in known locations
in a background that has no cold spots. The contrast-
detail phantom that we used was built at the depart-
ment of biomedical engineering at our hospital, based on
the design previously published by More´ et al. [10]. In
Figure 1, we show a transverse view of the design of the
phantom.
The phantom was constructed using polymethyl-
methacrylate (PMMA) and consists of six diﬀerent rows
with varying thicknesses of 1.3, 1.1, 0.9, 0.75, 0.6, 0.4 mm,
respectively, and each row having six holes with 2, 3, 4,
5, 7.5 and 10 mm diameter, respectively. The CD phan-
tom covers a range of contrasts, but the interpretation of
the acquisition data of the phantom is complicated by the
fact that for a ﬁxed acquisition time, hotspots of the same
size in diﬀerent rows not only have diﬀerent contrasts, but
also have a diﬀerent background per row. Clinical images
only show hotspots of varying sizes and contrasts in a
ﬁxed background. We, therefore, processed the dynamic
data obtained from the phantom to obtain a homogeneous
background for all holes of the phantom in the following
way: After the dynamic acquisition of the data, we iden-
tiﬁed the six rows of the phantom in the image. Next, we
created a composite normalized image of the original data.
This was done by selectively summing frames, in such a
way that the resulting image has the same background
everywhere. This is illustrated in Figure 2, where to pro-
duce a homogeneous background, the number of summed
frames is diﬀerent for each row: 17, 19, 21, 24, 28 and 33,
respectively. The statistics of the background regions of
interest (ROIs) are shown in Figure 2, and we see that
the image has a homogeneneous background (on aver-
age 103.5 counts/pixel with a standard deviation of 1.1
between the rows).
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Figure 1 Contrast-detail phantom. Schematic of the contrast detail phantom design. The dimensions of the phantom are 186 mm × 138 mm.
Within each row, the separation between the centres of the holes is 23 mm. The separation between the centres of the holes in adjacent rows is 31
mm. The depths of the holes in each row are 1.3, 1.1, 0.9, 0.7, 0.6 and 0.4 cm, respectively.
The contrast of the holes in each row of the phantom
depends, in ﬁrst approximation, on the thickness of the




1 − eμW l
]
− 1, (1)
where μa ( 0.17 cm−1 for 140 keV) is the linear atten-
uation coeﬃcient of accrylic, μw ( 0.15 cm−1 for 140
keV) is the linear attenuation coeﬃcient of water, h is the
height of the column for each hole, and l is the height of
the background columns. The contrast, as described by
Equation 1, is independent of the diameter of the holes
and of the acquisition time. In other words, the back-
ground counts are controlled by the acquisition time, but
the contrast will remain the same in principle. In Table 1,
the theoretical contrasts of the phantom are given includ-
ing the attenuation of the PMMAand excluding the partial
volume eﬀect.
For the measurements, we ﬁlled the phantom with
a concentration of 80 MBq of 99mTc in 500 ml of
water. The phantom was subsequently imaged with a
general-purpose (GP) collimator and a high-resolution
(HR) collimator. These collimators have diﬀerent res-
olution and sensitivity properties, with a sensitivity of
180 and 90 counts/MBq for the GP and the HR col-
limator, respectively. The ratio of these sensitivities
numerically equals 2.0, which means that to receive
the same number of counts, one needs to image twice
as long with the HR collimator compared to the GP
collimator.
The acquisition of the ﬁlled phantom was performed
using a dynamic acquisition mode with a frame duration
of 30 s for a total acquisition time of 60 min, using a
GP collimator. To compare the GP collimator and the HR
collimator, a second acquisition was made for both col-
limators with a total acquisition time of 16 min and a
frame duration of 10 s per frame. In Figure 3, we show
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Figure 2 Structure of composite normalized image. Example of a
composite normalized image. The numbers on the right show the
expected contrast of the holes in each row based on Equation 1 and
are also summarized in Table 1.
examples of the normalized phantom image for four dif-
ferent backgrounds for the GP and the HR collimator,
respectively.
The orientation of the images is such that in the verti-
cal direction, the contrast increases as we move down the
rows. In the horizontal direction, the holes of the phantom
become smaller from right to left, and due to the partial
volume eﬀect, the observed size of the holes levels oﬀ and,
instead, the contrast becomes smaller.
Analysis
The observability of a hotspot in a noisy background
depends not only on the contrast of the hotspot, but
also on the observed size of the hotspot and on its back-
ground. We therefore have performed a CNR analysis of








Overview of contrasts based on Equation 1 for each row.
both the patient data and the phantom data. The CNR is a
dimensionless parameter and deﬁned here as [11] follows:
CNR = CCOV,
where the contrast C is deﬁned with respect to a back-
ground region and given byC = (Nl−Nbg)/Nbg, whereNl
can be either the maximum or average number of counts
per pixel measured in the ROI that was drawn around
the hotspot. Because most of the hole diameters are com-
parable to or smaller than the pixel size of the camera,
we have used the maximum ROI value for our analysis.
Nbg is the average number of counts of the background.
The background ROIs for each row were chosen to be
as large as possible without overlapping with the holes in
each row. The coeﬃcient of variation (COV) is given by
COV = σbg/Nbg, where σbg is the standard deviation of
the background ROI.
The detectability of a hotspot by an observer is cor-
related with the CNR value of the hotspot. The Rose
criterion states that if the CNR of a hotspot becomes
smaller than 3 to 5, it becomes very diﬃcult to observe the
hotspot[11]. By reducing the acquisition time, we deter-
mined the number of hotspots that have a CNR smaller
than the Rose criterion. It is important to note that the
CNR analysis of the patient data was performed on the CC
and MLO views separately, which means that only con-
clusions about the detectability of a lesion on a separate
view can be made. For the phantom, we have deﬁned the
observability as the percentage of the holes in the phan-
tom that have a CNR greater than a given threshold value
(based on the Rose criterion). For example, if the observ-
ability of the phantom is 50% with a threshold of 3, this
means that 50% of the 36 holes of the phantom have a
CNRmax that is greater than 3. By determining the observ-
ability as a function of acquisition time, we can character-
ize the way in which the detectability of lesions increases
with increasing acquisition time for a given camera. We
repeated this procedure for a range of threshold values to
determine the dependency on the threshold value. As an
additional practical application of our method, we com-
pared the observability of the GP and the HR collimator,




To determine the average background counts, we man-
ually drew ROIs on all views. This includes views with
hotspots and views without hotspots. In Figure 4, we give
an overview of the measured background counts versus
administered activity after an acquisition time of 8 min for
each of the views. The average background of the patients
included in this study was 120 counts per pixel (range 64
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Figure 3 Examples of acquired GP and HR images. Example of normalized phantom images for data acquired with both GP and HR collimators.
to 195) after an acquisition time of 8 min with an average
administered activity of 723 MBq.
From the set of 49 views, the nuclear physician identi-
ﬁed 52 hotspots to be possibly clinically relevant. Next, we
determined the observed size and contrast of the hotspots
with respect to the background of the image. The results
are shown in Figure 5.
From Figure 5, we notice that the smallest observed
hotspots sizes are around 9 mm, and the lowest observed
contrasts are around 0.1. The CNR values of the identiﬁed
Figure 4Measured background counts in patients. Overview of measured background counts versus administered activity after 8 min. The plus
sign indicates the average activity and background counts.
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Figure 5 Observed lesion sizes and contrasts. Overview of
observed lesion sizes versus observed contrast.
hotspots are summarized in Table 2 for the various acqui-
sition times. We see that all indentiﬁed hotspots have a
CNRmax > 2.5 after the acquisition time of 8 min. For
this reason, we use CNRmax = 2.5 as our clinical refer-
ence value throughout this study. From Table 2, we see
that when we reduce the acquisition time by a factor of
4, three of the identiﬁed hotspots have a CNRmax < 2.5,
and visual inspection conﬁrmed that these hotspots were
no longer observed. In Figure 6, we show the correspond-
ing patient data for these three hotspots. We have marked
the background ROIs (dotted lines) and the three hotspots
(solid lines).
The hotspots which had both maximum and mean
CNR < 2.5 were not detectable when reviewed.
In summary, we see that for our patient group, the iden-
tiﬁed hotspots all have a CNRmax > 2.5. Reducing the
scanning time or, equivalently, patient dose by a factor of
3 does not lead to hotspots with CNRmax < 2.5.
Phantom data
To compare the phantom data acquired with the GP colli-
mator and patient datasets, we determined for the phan-
tom data for each acquisition time the average number
of background counts. The average background counts in
Figure 6 Example of CNRmeasurement in patient data. Three
patients with hotspots for which CNRmax ≤ 2.5 when the acquisition
time is reduced to 2 min. The dotted line corresponds to the
background ROI used, and the solid line marks the hotspot of interest.
The numbers shown correspond to the CNRmax within the ROI.
the phantom were then converted to an equivalent patient
acquisition time by using the fact that after an 8-min
acquisition, the average patient has 120 counts/pixel in the
background. To compare the HR and GP collimator, we
additionally took into account the diﬀerence in sensitivity
Table 2 Analysis of CNR data of patient data
Scantime (min) CNRmax ≤ 2.5 CNRmax > 2.5 CNRmax > 3 CNRmax > 4 CNRmax > 5
2 3 49 46 38 33
2.66 0 52 46 38 33
4 0 52 44 38 34
8 0 52 49 39 35
Overview of CNRmax for 52 hotspots at 2, 2.67, 4 and 8 min, respectively.
Dickerscheid et al. EJNMMI Research 2013, 3:21 Page 7 of 9
http://www.ejnmmires.com/content/3/1/21
between the two collimators. In Figure 7, we show the
observability of the GP collimator.
It can be seen from the ﬁgure that, independent of
the threshold value, the observability increases until the
acquisition time reaches 16 min and then levels oﬀ. The
current protocol uses an acquisition time of 8 min, which
lies right in the middle of the range where the observabil-
ity increases in the phantom. This suggests that increasing
the acquisition time of the protocol could result in a
higher observability for patient acquisitions as well. As an
additional practical application, we compared the observ-
ability of the GP and HR collimators.
As shown in Figure 8, the observability of the HR and
GP collimators is similar for each threshold value. To the
extent that CNR can be used as ameasure of image quality,
this means that images acquired with the HR collimator
have the same image quality as those acquired with the GP
collimator at the same acquisition time.
Discussion
In this study, we presented a CNR analysis of the BSGI
acquisition protocol at our hospital. We performed the
CNR analysis both on patient data and on data acquired
with a contrast-detail phantom. Using a dynamic acqui-
sition protocol, it was possible to create time-reduced
images for any acquisition time shorter than the acquisi-
tion time of our current protocol. The results from the
patient data analysis showed that the acquisition time
could have been reduced by a factor 3 without reducing
the number of observable hotspots on the separate views.
Additional visual observation of the identiﬁed hotspots
at the reduced acquisition times conﬁrmed our ﬁnding.
In contrast, the phantom study showed that increasing
Figure 7 Observability of the phantom. The observability (see text
for deﬁnition) of the phantom for a GP collimator versus acquisition
time in minutes. The diﬀerent lines correspond to diﬀerent threshold
values.
Figure 8 Comparision of the GP and HR collimator. Comparison of
the observability of the phantom for the GP collimator (solid line) and
the HR collimator (dashed line). The diﬀerent colors correspond to
diﬀerent threshold values.
the dose or acquisition time resulted in an increased
detectability of small lesions with low contrast. We believe
that the explanation for the discrepancy between our ﬁnd-
ings in the patient and phantom data is the small number
of patients included. If we include more patients we will
eventually ﬁnd tumours that can only be detected with
conﬁdence by an observer after the full acquisition time.
The fact that we see many patients with relatively large
tumours with a high CNR is related to the referral pro-
cedure for BSGI exams at our hospital. In most cases,
patients who are referred for a BSGI examination at our
hospital already underwent mammography, ultrasound
and MRI exams, and there is often a strong suspicion for
malignant disease; however, additional information about
the size or focality of the disease are required. Further-
more, based on our phantom data, we cannot exclude
the possibility that smaller lesions with low contrast were
in fact present in the patients that we used for our data
analysis and would have been detected using a longer
acquisition time or higher dose but remained undetected
with our current protocol.
To systematically investigate our ﬁndings of the patient
data analysis, we used a contrast-detail phantom. The rea-
son a contrast-detail phantom can be used to simulate
clinical practice is because the detection of breast can-
cer always involves the recognition of hot areas or lesions
in a background that have no cold spots. The contrast-
detail phantom simulates hotspots with contrasts ranging
from clearly visible to deﬁnitely invisble. From the results
of the patient data analysis (see Figure 5), we also see that
there is an overlap between the lowest contrasts seen in
the patient data and the higher contrasts of the hotspots
in the phantom. The way an observed contrast is realised
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depends on many factors such as the depth, size and
uptake of the physical lesion. A physically small lesion
deep inside the breast can result in the same observed
hotspot as amore superﬁcial and larger lesion with a lower
uptake of radioactive tracer.
Due to the partial volume eﬀect, the observed sizes of
the smallest lesions are signiﬁcantly larger than the true
sizes of the lesions. The smallest observed size of hotspots
from both the analysis of our patient data and from the
phantom study was around 10 mm. For the phantom, we
know that the true diameter sizes of the hotspots varied
from 1 to 10 mm. For the patient data, we could not cor-
relate the physical size of the lesions with the observed
hotspot sizes because we did not have the ﬁnal pathology
reports available. It should be noted that in the litera-
ture, tumours as small as 1 mm have been reported to be
detected with BSGI [3]. The smallest hole that we were
able to observe in this phantom study was 2 mm.
As mentioned, the contrast-detail phantom we used
does not simulate lesions at diﬀerent depths in the breast,
and although this would give additional and possibly valu-
able information, we believe this is less important for
this study, where we were able to show that hotspots
with lower contrasts become visible if we image longer.
We have also demonstrated that some holes will remain
undetectable by an observer, even after extremely long
acquisition times. It would therefore be interesting to
repeat the phantom measurements and analysis on diﬀer-
ent BSGI systems. To get an idea of the depth dependence
of the system resolution, we measured for our camera (see
Figure 9) how the system resolution changes as the dis-
tance to the detector increases. For the clinically relevant
range of compressed breast sizes, the resolution decreases
from 4.8 mm full width at half maximum (FWHM) at the
detector to 7.6 mm at a distance of 6.5 cm.When we com-
pared the resolution of our BSGI systemwith the standard
gamma cameras at our institute, we found that the resolu-
tion of the BSGI system deteriorates faster with increasing
distance, but for clinically relevant distances of up to 8
cm, these diﬀerences remained relatively small. Besides
the loss in resolution, deeper lesions will have a decreased
CNR due to scatter and attenuation.
Although the phantom is not an anatomical (3D) model
of a breast, it is a good simulator for (planar) scinti-
mammography images. The phantom we used is easy to
manufacture and easy to operate. Analysing the phan-
tom data required some reformatting of the data. From
the phantom study, we see that the optimal acquisition
time is around 16 min. In practice, long acquisition times
are undesirable. Arguably, acquisitions lasting 8 to 10 min
per view are reasonable. Longer acquisition times will
also likely introduce additional artefacts due to patient
movement. As a result, too long acquisition times are
clearly impractical, and somehow an upper limit to the
Figure 9 Resolution versus distance. The FWHM resolution as a
function of the distance to the detector.
acquisition time per view will have to be introduced. This
means that a higher sensitivity cannot be achieved by
longer acquisition times, and the only practical solution
to increase the chances of detecting more lesions for our
system is to increase the patient dose. Alternatively, a
dual-headed system has a greater sensitivity and should
lead to improved detectabillity as well. The CNR analysis
can be used on the patient data as well as on the phan-
tom data with the beneﬁts of reproducibility, consistency
and objectivity. As mentioned above, the Rose criterion
makes a connection between the CNR value of a lesion
and the probability of observing the lesion. The Rose cri-
terion, however, does not refer to a single threshold value
but to a range of values that separates lesions that can be
observed with near certainty from lesions that are almost
certainly unobservable. In this study, we showed that for
each threshold value in the range of 2.5 to 5, the observ-
ability of the phantom levels oﬀ at the same acquisition
time.
As an additional practical application, we compared the
observability of the GP and HR collimators and found that
the observability of the HR and GP collimators is similar
for each threshold value and acquisition time. It should
be mentioned that there are also dual-headed breast-
speciﬁc gamma cameras based on CZT technology, whose
scanning technique is equivalent to the single-head con-
ﬁguration. The dual-headed cameras have an even greater
sensitivity than the single-headed conﬁgurations, and a
proof of concept evaluation in patients using 296 MBq
has indicated that further dose reduction seems feasible
[6,7]. The downside of the dual-headed cameras is the sig-
niﬁcantly higher cost, and the modality cannot be moved
around as easily. To quantify the diﬀerences between the
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single- and dual-headed cameras, it would be interest-
ing to compare the two modalities directly using the CD
phantom and the CNR analysis presented here.
Conclusion
In summary, we found that although a dose reduction by
a factor 3 in an initial study of 13 patients would not have
lead to a reduced number of observable hotspots in each
of the separate views acquired, our phantom study showed
that a further dose reduction of BSGI scans of 8 min/view
with 740 MBq might result in a reduced sensitivity for
lesion detection, whereas increasing the acquisition time
and/or activity might result in a higher sensitivity for
lesion detection. At our hospital, BSGI is used for a patient
group that has a high incidence of malignant disease, and
the main clinical question is to characterize the extent
and focality of the disease because this has important
consequences for the course of treatment. An increase
of the administered activity might therefore be justiﬁed,
although a detailed radiation risk analysis should be per-
formed to determine how much the activity might be
increased to achieve an optimal detection possibility of
small lesions in our patient group.
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